[HTML][HTML] Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications
H Zhang, K Yang, F Chen, Q Liu, J Ni, W Cao… - Frontiers in …, 2022 - frontiersin.org
The CCL2-CCR2 axis is one of the major chemokine signaling pathways that has received
special attention because of its function in the development and progression of …
special attention because of its function in the development and progression of …
[HTML][HTML] Tumour-associated macrophages: versatile players in the tumour microenvironment
ZZ Ji, MKK Chan, ASW Chan, KT Leung… - Frontiers in Cell and …, 2023 - frontiersin.org
Tumour-Associated Macrophages (TAMs) are one of the pivotal components of the tumour
microenvironment. Their roles in the cancer immunity are complicated, both pro-tumour and …
microenvironment. Their roles in the cancer immunity are complicated, both pro-tumour and …
[HTML][HTML] Functional roles of chemokine receptor CCR2 and its ligands in liver disease
S She, L Ren, P Chen, M Wang, D Chen… - Frontiers in …, 2022 - frontiersin.org
Chemokines are a family of cytokines that orchestrate the migration and positioning of
immune cells within tissues and are critical for the function of the immune system. CCR2 …
immune cells within tissues and are critical for the function of the immune system. CCR2 …
S100A8 and S100A9 in Cancer
Y Chen, Y Ouyang, Z Li, X Wang, J Ma - Biochimica et Biophysica Acta …, 2023 - Elsevier
Abstract S100A8 and S100A9 are Ca 2+ binding proteins that belong to the S100 family.
Primarily expressed in neutrophils and monocytes, S100A8 and S100A9 play critical roles in …
Primarily expressed in neutrophils and monocytes, S100A8 and S100A9 play critical roles in …
[HTML][HTML] CXCL12-CXCR4/CXCR7 axis in cancer: From mechanisms to clinical applications
Y Yang, J Li, W Lei, H Wang, Y Ni, Y Liu… - … journal of biological …, 2023 - ncbi.nlm.nih.gov
Cancer is a multi-step disease caused by the accumulation of genetic mutations and/or
epigenetic changes, and is the biggest challenge around the world. Cytokines, including …
epigenetic changes, and is the biggest challenge around the world. Cytokines, including …
[HTML][HTML] Targeting macrophages: a novel treatment strategy in solid tumors
M Liu, L Liu, Y Song, W Li, L Xu - Journal of Translational Medicine, 2022 - Springer
In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are the most
abundant immune cells, which act as a key regulator in tumorigenesis and progression …
abundant immune cells, which act as a key regulator in tumorigenesis and progression …
[HTML][HTML] The cytokine network in colorectal cancer: Implications for new treatment strategies
H Braumüller, B Mauerer, J Andris, C Berlin, T Wieder… - Cells, 2022 - mdpi.com
Colorectal cancer (CRC) is one of the most frequent tumor entities worldwide with only
limited therapeutic options. CRC is not only a genetic disease with several mutations in …
limited therapeutic options. CRC is not only a genetic disease with several mutations in …
The role of macrophages in the tumor microenvironment and tumor metabolism
P Sadhukhan, TY Seiwert - Seminars in Immunopathology, 2023 - Springer
The complexity and plasticity of the tumor microenvironment (TME) make it difficult to fully
understand the intratumoral regulation of different cell types and their activities …
understand the intratumoral regulation of different cell types and their activities …
Tumor-associated macrophages employ immunoediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy
Tumor-associated macrophages (TAMs) constitute the most prolific resident of the tumor
microenvironment (TME) that regulate its TME into tumor suppressive or progressive milieu …
microenvironment (TME) that regulate its TME into tumor suppressive or progressive milieu …
[HTML][HTML] Strategies for heating up cold tumors to boost immunotherapies
DJ Zabransky, M Yarchoan… - Annual Review of Cancer …, 2023 - annualreviews.org
Immune checkpoint inhibitors induce significant and durable treatment responses in about
20% of all cancers, but many patients have natural resistance to current immunotherapies …
20% of all cancers, but many patients have natural resistance to current immunotherapies …